funding is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Caleres, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 6.3.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Lands' End
funding is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Caleres, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 6.3. Source depth averages 4 original sources per story, versus 2.9 across the same-window beat baseline. Lands' End appears in 1 tracked Healthcare story from March 20, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Lands' End. Shared-story counts are live from our verified record — not editorial picks.
Curis (CRIS) has successfully pivoted to a clinical-stage oncology focus, securing a cash runway into 2027 through a strategic asset sale and PIPE financing. Meanwhile, broader retail earnings from Torrid and Caleres reveal significant margin pressures from tariffs, signaling a complex macro environment for healthcare supply chains.